- Tytuł:
- Production of [103Pd]Bleomycin complex for targeted therapy
- Autorzy:
-
Jalilian, A.
Yari-Kamrani, Y.
Sadeghi, M. - Powiązania:
- https://bibliotekanauki.pl/articles/147472.pdf
- Data publikacji:
- 2006
- Wydawca:
- Instytut Chemii i Techniki Jądrowej
- Tematy:
-
palladium-103
palladium(II) complexes
radiolabeling
bleomycin complexes
radiopharmaceuticals
cyclotron
targeted therapy - Opis:
- Due to the anticancer properties of bleomycin (BLM) complexes, production of [103Pd]bleomycin ([103Pd]BLM) was targeted. Palladium-103 (T1/2 = 16.96 d) was produced via the 103Rh(p,n)103Pd nuclear reaction using a natural rhodium target. Proton energy was 18 MeV with 200 mA irradiation for 15 h (final activity 25.9 GBq of 103Pd2+, RCP > 95%, radionuclidic purity > 99%). 103Pd was separated from the irradiated target by anion exchange using a Dowex 1´8 (Cl-)/100-200 mesh resin in the form of Pd(NH3)2Cl2 in order to react with bleomycin to yield [103Pd]BLM. Chemical purity of the final product was in accordance to the accepted limits. [103Pd]BLM was prepared with a radiochemical yield of more than 98% at 80°C in 30 min. The labeling reaction was optimized for time, temperature and ligand concentration. Radiochemical purity of more than 99% was obtained using RTLC with specific activity of about 370 MBq/mmol. The stability of the tracer was checked in the final product and presence of human serum at up to 3 h. The complex was stable in human serum at 37°C up to 2 h of incubation. Biodistribution studies using a SPECT system performed in normal rats in the first 2-3 h.
- Źródło:
-
Nukleonika; 2006, 51, 2; 119-123
0029-5922
1508-5791 - Pojawia się w:
- Nukleonika
- Dostawca treści:
- Biblioteka Nauki
Artykuł